SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases
16 references·0 citing·53 second hop
Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases (2017)Budgetary Impact and Cost Drivers of Drug…Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL) (2017)Recommendations from the Euro…Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries (2015)Access to Orphan Drugs: A Com…Shining a light in the black box of orphan drug pricing (2014)Shining a light in the black …Orphan drugs policies: a suitable case for treatment (2014)Orphan drugs policies: a suit…Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders (2014)Incremental cost per quality-…Social Value Orientation (2013)Social Value OrientationA Pilot Study of Multicriteria Decision Analysis for Valuing Orphan Medicines (2013)A Pilot Study of Multicriteri…Orphan drug development: an economically viable strategy for biopharma R&D (2012)Orphan drug development: an e…Pricing and reimbursement of orphan drugs: the need for more transparency (2011)Pricing and reimbursement of …Estimating the budget impact of orphan medicines in Europe: 2010 - 2020 (2011)Estimating the budget impact …Arzneiverordnungs-Report 2011 (2011)Arzneiverordnungs-Report 2011Translation of rare disease research into orphan drug development: disease matters (2009)Translation of rare disease r…Orphan drugs and the NHS: should we value rarity? (2005)Orphan drugs and the NHS: sho…Empiricism, ethics and orthodox economic theory: what is the appropriate basis for decision-making in the health sector? (2004)Empiricism, ethics and orthod…Eliciting public preferences for healthcare: a systematic review of techniques (2001)Eliciting public preferences …Citizens and rationing: analysis of a European survey (1999)Citizens and rationing: analy…The Discovery of Grounded Theory; Strategies for Qualitative Research (1968)SERVQUAL: A multiple-Item Scale for measuring consumer perceptions of service quality (1988)Health Measurement Scales: A Practical Guide to Their Development and Use (1989)Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D (2005)Deleting ‘irrational’ responses from discrete choice experiments: a case of investigating or imposing preferences? (2006)Using the Nominal Group Technique: how to analyse across multiple groups (2014)Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers (2007)The importance of new companies for drug discovery: origins of a decade of new drugs (2010)Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications (2017)Estimating the clinical cost of drug development for orphan versus non-orphan drugs (2019)Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy (2023)Culture Shift in Advanced Industrial Society (1990)Citizens and the State (1998)European Health Care Reform: Analysis of Current Strategies (1999)Does it matter who you are or what you gain? an experimental study of preferences for resource allocation (2002)Cross-national agreement on disability weights: the European Disability Weights Project (2003)Citizen Participation in Patient Prioritization Policy Decisions: An Empirical and Experimental Study on Patients' Characteristics (2012)QALYfying the value of life. (1987)Explaining the Identifiable Victim Effect (1997)A rational framework for decision making by the National Institute For Clinical Excellence (NICE) (2002)Public healthcare resource allocation and the Rule of Rescue (2008)SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE‐BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS‐SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN (2012)Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework (2017)Prospect Theory: An Analysis of Decision under Risk (1979)Prospect theory: An analysis of decision under risk (1988)The dark core of personality. (2018)Personality and prosocial behavior: A theoretical framework and meta-analysis. (2019)Theory of games and economic behavior (2019)Prosocial behavior and altruism: A review of concepts and definitions (2021)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)National Institute for Clinical Excellence and its value judgments (2004)QALY maximisation and people's preferences: a methodological review of the literature (2004)Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? (2012)Severity of illness and priority setting in healthcare: A review of the literature (2009)Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force (2011)Multiple Criteria Decision Analysis for Health Technology Assessment (2012)Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework (2014)Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment (2016)Official Journal of the European Communities (1984)Rare diseases, orphan drugs and their regulation: questions and misconceptions (2010)Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives (2012)Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries (2013)Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group (2018)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. (2009)Socio-economic burden of rare diseases: A systematic review of cost of illness evidence (2014)Overcoming Challenges Facing Advanced Therapies in the EU Market (2016)Why rare diseases are an important medical and social issue (2008)A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development? (2018)Comparing access to orphan medicinal products in Europe (2019)Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut) (2019)
this work references cited by second hop

References

  • 2001Eliciting public preferences for healthcare: a systematic review of techniques641 cited
  • 2013Social Value Orientation375 cited
  • 2015Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries278 cited
  • 2011Pricing and reimbursement of orphan drugs: the need for more transparency261 cited
  • 2005Orphan drugs and the NHS: should we value rarity?229 cited
  • 2012Orphan drug development: an economically viable strategy for biopharma R&D161 cited
  • 2011Estimating the budget impact of orphan medicines in Europe: 2010 - 2020133 cited
  • 2013A Pilot Study of Multicriteria Decision Analysis for Valuing Orphan Medicines111 cited
  • 2017Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)103 cited
  • 1999Citizens and rationing: analysis of a European survey96 cited
  • 2014Orphan drugs policies: a suitable case for treatment84 cited
  • 2009Translation of rare disease research into orphan drug development: disease matters75 cited
  • 2014Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders73 cited
  • 2011Arzneiverordnungs-Report 201172 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2004
Empiricism, ethics and orthodox economic theory: what is the appropriate basis for decision-making in the health sector?
64 cited
  • 2014Shining a light in the black box of orphan drug pricing60 cited
  • Cited by

    No citing works inside the corpus for this window.